Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution

2026-03-03 13:50:10 ET

The last time I spoke about Prothena Corporation plc ( PRTA ), it was in a Seeking Alpha article entitled " Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place ." I went over two of its main clinical programs, which were the use of monoclonal antibodies to treat patients with neurodegenerative disorders. One program involves the company partnering with Roche ( RHHBY ) to evaluate the use of anti-alpha-synuclein antibody prasinezumab for the treatment of patients with early-stage Parkinson's Disease [PD] in the ongoing phase 3 PARAISO study....

Read the full article on Seeking Alpha

For further details see: